TNDM - タンデム・ダイアベティス・ケア （Tandem Diabetes Care Inc.）

https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-71-at-barclays-432SI-3013601

Tandem Diabetes Care Inc (NASDAQ: TNDM ) reported Q4 FY22 sales of $220.50 million , missing the consensus of $221.83 million. The automated insulin delivery technology maker posted adjusted losses of $(0.46) million, compared to an income of $10.81 million a year ago. Tandem … Full story available on Benzinga.com

https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-40-at-baird-432SI-3011879

https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-50-at-piper-sandler-432SI-3011822

Tandem Diabetes Care, Inc. (NASDAQ:NASDAQ:TNDM) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ETCompany ParticipantsSusan Morrison - EVP & Chief Administrative OfficerJohn…

As of Wednesday, Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock closed at $42.52, up from $41.54 the previous day. While Tandem Diabetes Care Inc. has overperformed by 2.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TNDM fell by -71.69%, with highs and lows ranging from $155.86 […]

Tandem Diabetes Care Inc (NASDAQ: TNDM ) has agreed to acquire AMF Medical SA , the privately held Swiss developer of the investigational Sigi Patch Pump. It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through … Full story available on Benzinga.com

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it acquired AMF Medical, maker of the Sigi patch pump for insulin delivery. Switzerland-based AMF Medical currently develops the Sigi patch pump and does not offer it commercially. The system received FDA breakthrough device designation just over one year ago. AMF Medical designed Sigi as an ergonomic, rechargeable […] The post Tandem Diabetes Care to acquire patch pump maker AMF Medical appeared first on Drug Delivery Business .

Tandem Diabetes Care (TNDM) has agreed to acquire Swiss insulin patch pump developer, AMF Medical for CHF 62.4M in cash due at closing.The agreement covers a previous strategic…

Tandem Diabetes Care Inc. , an insulin delivery and diabetes technology company, said Tuesday it has entered a definitive agreement to acquire AMF Medical SA, a Swiss privately held maker of the Sigi Patch Pump. The pump is currently under development and is not commercially available. "It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges and its compatibility with automated insulin delivery technology," the San Diego-based Tandem said in a statement. Tandem will pay 62.4 million Swiss francs ($66.4 million) upon closing, as well as a previous investment of 8 million Swiss francs, and up to 129.6 million francs of earnout payments upon achievement of certain milestones. The deal is expected to close in January. Tandem stock was not active premarket, but has fallen 71% in the year to date, while the S&P 500 has fallen 16%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.

https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-75-at-citi-432SI-2905650

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2022 results after the financial markets close on Wednesday, November 2, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2022 financial and operating

In the last trading session, 1.04 million Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares changed hands as the company’s beta touched 0.94. With the company’s per share price at $45.33 changed hands at -$2.09 or -4.41% during last session, the market valuation stood at $2.90B. TNDM’s last price was a discount, traded about -243.83% off its … Tandem Diabetes Care Inc. (NASDAQ: TNDM) Prices Could Soar To Much Higher Levels In Coming Months Read More »

Tandem Diabetes Care''s bottom-line fundamentals have been softening on a sequential basis since FY21. See why I rate TNDM stock as hold.

Tandem Diabetes Care Inc. (NASDAQ:TNDM) has a beta value of 0.92 and has seen 1.38 million shares traded in the last trading session. The company, currently valued at $3.60B, closed the last trade at $54.68 per share which meant it lost -$2.58 on the day or -4.51% during that session. The TNDM stock price is … Tandem Diabetes Care Inc. (TNDM) Looks Set To Grow At A Great Clip In 2022 Read More »